Free Trial

Cadrenal Therapeutics Q4 2023 Earnings Report

Cadrenal Therapeutics logo
$15.42 -1.43 (-8.49%)
As of 03/10/2025 04:00 PM Eastern

Cadrenal Therapeutics EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.09
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Cadrenal Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cadrenal Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

Cadrenal Therapeutics Earnings Headlines

Has Trump finally met his match?
Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?
Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial
See More Cadrenal Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cadrenal Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cadrenal Therapeutics and other key companies, straight to your email.

About Cadrenal Therapeutics

Cadrenal Therapeutics (NASDAQ:CVKD) operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

View Cadrenal Therapeutics Profile

More Earnings Resources from MarketBeat